Ostéonecrose des maxillaires en rapport avec la prise de bisphosphonates: que faire [Management of complications of bisphosphonates in oncology patients: jaw osteonecrosis].

Détails

ID Serval
serval:BIB_F9403A0F6A1C
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Ostéonecrose des maxillaires en rapport avec la prise de bisphosphonates: que faire [Management of complications of bisphosphonates in oncology patients: jaw osteonecrosis].
Périodique
Revue Médicale Suisse
Auteur(s)
Madrid C., Jaques B., Bouferrache K., Broome M.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Statut éditorial
Publié
Date de publication
05/2007
Volume
3
Numéro
112
Pages
1322, 1324-6, 1329-31
Langue
français
Notes
Publication types: English Abstract ; Journal Article ; Review
Publication Status: ppublish
Résumé
The first report of jaw osteonecrosis in patients treated with bisphophonates was published in 2003. Since then, not a week goes by without new cases being described in the literature. The vast majority of patients treated with IV bisphosphonates are oncology patients, although numbers of patients with osteonecrosis treated for osteoporosis and Paget's disease are also rising. In the absence of any established treatment, it is generally agreed that initiating pretherapeutic prevention strategies in oncology patients is advisable. Treatment of a recognised osteonecrosis is discussed, with preference being given for a conservative approach rather than aggressive surgical procedures. Our team suggests classifying affected patients into two categories according to the lesions: disabling or non-disabling. An appropriate treatment plan can then be put into place.
Mots-clé
Antineoplastic Agents/administration & dosage, Antineoplastic Agents/adverse effects, Bone Density Conservation Agents/administration & dosage, Bone Density Conservation Agents/adverse effects, Diphosphonates/administration & dosage, Diphosphonates/adverse effects, Humans, Jaw Diseases/chemically induced, Jaw Diseases/therapy, Neoplasms/complications, Neoplasms/therapy, Osteolysis/etiology, Osteolysis/prevention & control, Osteonecrosis/chemically induced, Osteonecrosis/therapy
Pubmed
Création de la notice
28/01/2008 12:55
Dernière modification de la notice
03/03/2018 22:53
Données d'usage